Standout Papers

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced ... 2017 2026 2020 2023 332
  1. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial (2017)
    Beatrice Seddon, Sandra J. Strauss et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

AI in diagnostic imaging: Revolutionising accuracy and efficiency
2024 Standout
Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
2 intermediate papers

Works of Maria Marples being referenced

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
2017 Standout
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
2014

Author Peers

Author Last Decade Papers Cites
Maria Marples 500 174 350 30 700
U. Matulonis 341 123 246 32 584
Douglas Adkins 353 74 383 18 638
Ketki Tendulkar 335 162 253 22 618
Alejandro Yovine 416 126 420 24 718
Bernard Marquès 278 83 545 24 677
Geraldine Goss 439 136 482 24 791
Roman Groisberg 418 175 371 49 695
Ashwin Shahir 393 63 465 26 651
Daniela Katz 314 72 352 29 601
Veridiana Pires de Camargo 519 65 622 26 843

All Works

Loading papers...

Rankless by CCL
2026